Latest Research
All publications from the Cancer3.AI database, newest first.
New Binding Sites for JAK2 Inhibition in Myeloproliferative Neoplasms: Structural Insights, Therapeutic Potential, and Future Directions.
Zhao G, et al
Researchers publishing in ChemMedChem have conducted a comprehensive review of next-generation strategies for inhibiting JAK2, a key enzyme whose mutation drives myeloproliferative neoplasms (MPNs), a group of blood cancers characterized by the overproduction of blood cells. While the first wave of JAK2 inhibitors that block the enzyme's ATP-binding pocket has proven clinically useful, these drugs suffer from off-target toxicity, an inability to significantly reduce the burden of mutant cancer cells, and the eventual development of drug resistance. The review focuses on newly identified binding sites on the JAK2 protein — including allosteric pockets, covalent attachment points, and regulatory pseudokinase domains — that offer promising alternative targets for drug design with improved selectivity and the potential to overcome resistance. By synthesizing structural, computational, and early clinical data, the authors map out both the therapeutic advantages of these novel approaches and the practical challenges that remain, such as confirming that the new sites are truly druggable, optimizing how long a drug stays bound to its target, and ensuring the safety of irreversible covalent inhibitors. The review ultimately proposes a strategic roadmap for combining these new inhibitor classes with existing therapies to achieve more durable responses in MPN patients. This work is important for oncologists and medicinal chemists because it reframes the direction of JAK2 drug discovery at a time when patients urgently need treatments that go beyond symptom control toward genuine disease modification.
ChemMedChem
Source →Secondary Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia Following Prolonged Lenalidomide Maintenance in Multiple Myeloma.
Thomas J, et al
Researchers report a rare case of secondary B-cell acute lymphoblastic leukemia (B-ALL) developing in a 62-year-old woman with multiple myeloma who had received lenalidomide maintenance therapy for over four years. Lenalidomide is a widely used drug that extends survival in multiple myeloma, but it is known to increase the risk of second cancers, most commonly myelodysplastic syndromes and acute myeloid leukemia. In this patient, B-ALL was diagnosed nearly one year after lenalidomide was stopped, presenting with bruising and low platelet counts, and confirmed by bone marrow biopsy showing a complex chromosomal abnormality without the Philadelphia chromosome. The patient was successfully treated with an intensive chemotherapy regimen combining mini-hyper-CVD with inotuzumab ozogamicin and rituximab, followed by an allogeneic stem cell transplant. This case highlights that B-ALL, although rare, can emerge as a late complication of long-term lenalidomide maintenance, sometimes appearing well after the drug has been discontinued. Clinicians should maintain heightened vigilance for unusual blood abnormalities in multiple myeloma survivors, even years after completing maintenance therapy.
Journal of medical cases
Source →Isocitrate dehydrogenase mutations as potential tumour agnostic targets.
Macarulla T, et al
This review article examines mutations in the isocitrate dehydrogenase (IDH) family of enzymes and their role as potential therapeutic targets across multiple cancer types. IDH mutations cause the abnormal production of an oncometabolite called 2-hydroxyglutarate (2-HG), which disrupts normal epigenetic regulation by causing widespread hypermethylation of DNA and histones, ultimately blocking cell differentiation and driving tumor growth. These mutations are found in several cancers including cholangiocarcinoma (13%), acute myeloid leukemia (33%), glioma (73%), and chondrosarcoma (56%), though their biological effects and prognostic significance differ across tumor types. Notably, IDH mutations serve as a defining diagnostic and prognostic marker specifically in glioma, while their prognostic impact in other cancers remains unclear. The authors highlight a critical unmet medical need: despite IDH mutations being actionable drug targets, approved and effective therapies remain limited across most IDH-mutant cancer types. This review calls attention to the promise of tumor-agnostic therapeutic strategies that could target IDH mutations regardless of the tissue of origin, potentially benefiting a broad population of cancer patients.
EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]
Source →Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers.
Bridgewater J, et al
Researchers reviewed the clinical progress of drugs that target mutant isocitrate dehydrogenase (mIDH), a genetic alteration found in several cancers including acute myeloid leukaemia (AML), bile duct cancer (cholangiocarcinoma), brain tumours (glioma), and bone cancer (chondrosarcoma). The drug ivosidenib combined with azacitidine significantly improved overall survival in mIDH1 AML patients, cutting the risk of death by 58% compared to placebo in the phase 3 AGILE trial, while ivosidenib also showed survival benefits in bile duct cancer in the ClarIDHy trial. The phase 3 INDIGO trial demonstrated that vorasidenib reduced the risk of disease progression by 61% compared to placebo in patients with grade 2 mIDH glioma, a brain tumour type with historically limited treatment options. An ongoing phase 3 trial called CHONQUER is now evaluating ivosidenib in patients with inoperable, progressive mIDH1 chondrosarcoma, a rare bone cancer. Across all studies, these targeted therapies were generally well tolerated by patients. These advances signal a meaningful shift toward precision medicine for mIDH-driven cancers, offering renewed hope to patients who previously had few effective treatment options.
EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]
Source →Nationwide trends and outcomes of transsphenoidal pituitary surgery: A 15-year analysis from the public healthcare system.
Pellozo Cerqueira B, et al
Researchers conducted the first nationwide study in Latin America examining transsphenoidal pituitary surgery — a minimally invasive procedure to remove tumors near the pituitary gland — using 15 years of data from Brazil's public health system. Analyzing 8,934 surgeries performed between 2010 and 2024, the study found that surgical care is heavily concentrated in the Southeast region, which accounted for 65% of all procedures, while patients in the North and Northeast have significantly limited access to this treatment. The overall in-hospital mortality rate was low at 1.4%, and average hospital stays declined over time, suggesting improved surgical safety and efficiency. However, the average reimbursement paid by Brazil's public health system was only about US$878 per hospitalization — far below international standards — raising concerns about the financial sustainability of providing this care. These findings highlight the urgent need to address geographic inequalities in neurosurgical access and to reassess public funding levels to ensure equitable, high-quality care for all Brazilian patients with pituitary tumors.
Surgical neurology international
Source →